Brought to you by 
Roche, ParAllele BioScience study genetic basis of diabetes
20 May 2004
Executive Summary
ParAllele BioScience (haplotype, sequence, gene expression, and single nucleotide polymorphism technology) and Roche have signed an agreement to research the genetic factors contributing to Type II diabetes for the purpose of developing therapeutics and diagnostics.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Concluded
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche, ParAllele BioScience study genetic basis of diabetes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice